


# Site Map

Universitätsmedizin Mainz



Registration required!!

Please register until 28th of September 2023 at  
<https://survey.zdv.uni-mainz.de/index.php/193174?lang=en>


## Universitätsmedizin

der Johannes Gutenberg-Universität Mainz,  
Langenbeckstr. 1, 55131 Mainz

## Organisation:

Dominik Siegl/Doro Thies/Sandrine Jansky  
Phone: 06131-17-9682  
Email: [domsiegl@uni-mainz.de](mailto:domsiegl@uni-mainz.de)

stock.adobe.com-soraya



The Institute of Translational Immunology presents

## ERA PerMed Mini-Symposium

Unleashing the power of personalized  
medicine for the treatment of cancer:  
Different approaches, same goal

Lecture hall 706

5th of October 2023, 09:15 - 16:00

#ERA PerMed



UNIVERSITÄTSmedizin.

MAINZ

# ERA PerMed Mini-Symposium

**Unleashing the power of personalized medicine for the treatment of cancer: Different approaches, same goal**

**Dear colleagues,**

we are happy to welcome you to our first ERA PerMed Mini-Symposium with the title: „Unleashing the power of personalized medicine for the treatment of cancer: Different approaches, same goal.“

ERA PerMed is a new ERA-Net Cofund, supported by 32 partners from 23 countries and cofunded by the European Commission to launch innovative research projects in personalized medicine.

Ernesto Bockamp            Detlef Schuppan  
ERA PerMed                Head of the TIM Mainz  
Coordinator Mainz

## Program

**09.15 am Welcome**

**09.30 am Targeting the MAPK pathways in human cancer**  
Krishnaraja Rajalingam, Mainz

**10.05 am Clinical trial evaluation in non-small cell lung cancer (NSCLC) patients: Updates and challenges**  
Savvas Petanidis, Thessaloniki

**10.40 am Multimodal therapy of fibrosis and cancer: Targeting metabolism and the microenvironment**  
Detlef Schuppan, Mainz

## Coffee Break

**11.30 am Cell of origin and molecular drivers for non-small cell lung cancer**  
Rocio Sotillo, Heidelberg

**12.05 pm Application of Immunotherapy in the treatment of NSCLC: Ethical perspectives on the cost-effectiveness justification and evaluation**  
Hamideh Mahidiani, Mainz

**12.40 pm Activation of canonical WNT signaling in tumor-surrounding immune cells promotes immune suppression and is a hallmark of non-small cell lung cancer (NSCLC)**  
Ernesto Bockamp, Mainz

## Lunch Break

**2.15 pm Preclinical valuation of Sotorasib and Therapy-X combination for the treatment of lung cancer**  
Monica Musteanu, Madrid

**2.50 pm Personalized lung cancer therapies with chimeric antigen receptor T cells (CAR T cells)**  
Sandrine Jansky, Mainz

**3.25 pm Comprehensive characterization of Lung Squamous Cell Cancer lead to new patient subgroups and novel opportunities for precision oncology**  
Álvaro C. Ucero, Madrid

**4.00 pm Final discussion and concluding remarks**  
Sponsored by